Schistosomes Flashcards

1
Q

Modified Type 2 Response

A

A mix of a strong type 2 dominated response and a regulatory response in helminth infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Potential roles for the modified type 2 response

A

I. Wound healing
II. Restrict the level of reinfection/establishment of new worms
III. Kill and/or isolate tissue-damaging life cycle stages
IV. Restrict the level of Th1-mediated inflammation to the parasites in order to limit immunopathology

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Basic Schistosome Lifecycle

A
Eggs
Miracidia (snail)
Cercariae (human)
Schistomulae
Adult worms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Granuloma components

A

Lymphocytes
Eosinophils
Macrophages
Fibroblasts (=fibrosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pathogenesis of S. haematobium

A

Ureter and bladder disfunction
Increased risk of bladder carcinoma
Eggs lodged - infertility, bleeding, risk of HIV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Egg granuloma over time

A

Miracidiae insides the egg dies
Granuloma dissolves
Fibrosis remains

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Function of the T-cell mediated granuloma

A

Protects the host tissue from toxic egg products and rapid death as seen in T cell-deficient mice

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What stimulates the Th2 response?

A

Presence of schistosome eggs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Th2 cytokines involved in granuloma formation

A

IL-4 and IL-13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cytokine that fibrosis in granulomas are dependent on

A

IL-13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Regulartion of schistosome granuloma

A

IL-13 Rα2
IFN-γ/IL-12
M2 macrophages (AAM)
IL-10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

IL-13 Receptors

A

IL-4Rα/IL-13Rα1

IL-13 Rα2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Key control mechanism of hepatic fibrosis

A

IL-13 Rα2 (IL-13 decoy receptor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

SM2

A

Genetic locus associated with familial distribution of hepatic fibrosis and portal hypertension
Influences sever liver fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IFN-gamma Regulatory Role

A

Polymorphisms associated with severe hepatic fibrosis in S. mansoni

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Polarisation to Th1 response

A

No inflammation and rapid death

17
Q

Polarisation to Th2 response

A

Fibrosis and increased mortality

18
Q

Properties of M2 Macrophages

A
  • Induced by IL-4 and IL-13
  • Generate low levels of toxic radicals (nitrogen and oxygen intermediates)
  • Express Arginase-1, Mannose Receptor, Fizz-1, YM-1
  • Marked anti-proliferative properties
  • Secrete anti-inflammatory cytokines, IL-10 and TGF-β
  • Produce matrix proteins
19
Q

How do M2 cells regulate granuloma size?

A

By suppressing Th2 cytokine production and T cell proliferation

20
Q

IL-10 involvement in granulomas

A

Associated with reduction of granulomatous pathology

Inhibits fibrosis

21
Q

Cytokines associated with resistance to schistosome re-infection

A

High IgE and low IgG4 against worm antigens

High IL-4 and IL-13 levels

22
Q

IgG4 involvement in parasite control

A

May block IgE binding to schistosomula and subsequent recruitment of eosinophils
Negative impact on parasite resistance

23
Q

Sm1 gene

A

Co-dominant gene that controls the level of Th2 responsiveness, and ratio of Th2:Th1 cytokines

24
Q

What does Sm1 encode?

A

Evidence of an association with an increase in IL-13 expression

25
Q

Three suggested types of schistosome vaccine

A

1) a prophylactic vaccine to prevent or reduce infection and indirectly transmission
2) a vaccine to reduce or eliminate re-infection intensity or transmission force by reducing female worm survival or egg production
3) a therapeutic vaccine to reduce disease but not affect infection or transmission